SS Innovations International
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| SS Innovations International (SSII) | 529.00M | -44.08 | 9.91 | 0.00% |
| Abbott Laboratories (ABT) | 172.35B | 32.23 | 3.37 | 2.45% |
| Medtronic (MDT) | 113.18B | 21.79 | 2.25 | 3.22% |
| Stryker Corp (SYK) | 106.38B | 28.74 | 4.43 | 1.25% |
| Boston Scientific (BSX) | 61.93B | 17.30 | 2.48 | 0.00% |
| Edwards Lifesciences (EW) | 49.12B | 49.54 | 4.63 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 36.0% below Morningstar's fair value estimate.
Fair value
While SS Innovations International Inc may seem inexpensive after its substantial price decline over the past year, we've limited its rating to 3 stars to account for the possibility that it may represent a value trap. The stock currently trades at a 24% discount to our quantitative fair value estimate of $3.60 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's solid growth bolsters our fair value estimate. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 122.9% falls in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.
Conversely, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to EBITDA ratio of 237.4, for example, ranks in the top 10% compared with peers globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-10-09 20:02:38 · For reference only, not investment advice and not tailored to your situation.
SS Innovations International discussion 0 comments